Guest
Updated COVID-19 vaccines are recommended for everyone 6 months and older and will be available by the end of this week ‘Safe and effective’ Estimated hospitalizations prevented per 1,000,000 vaccine doses 12 -17 years 19-95 hospitalizations, 5-19 ICU admissions, and perhaps one death. 5 – 11 years 16 hospitalizations, (based on Spring 2023 data) 18 – 49 years 75 hospitalizations, (based on Spring 2023 data) Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults Pfizer vaccines excess risk of serious adverse events (Higher than placebo baseline) 10.1 per 10,000 101 per 100,000 1,010 per 1,000,000 Moderna vaccines excess risk of serious adverse events (Higher than placebo baseline) 15.1 per 10,000 151 per 100,000 1,510 per 1,000,000 In Western Australia ~/media/Corp/Documents/Health-for/Immunisation/ Total AEFI rate following a COVID-19 vaccine 264.1 per 100,000 doses 2,641 per 1,000,000 doses March 22 Moderna chief executive defended the company's plan to quadruple the price of its COVID-19 vaccine, $130 per dose Pfizer last year suggested $110 to $130 per dose. From FDA to MHRA: are drug regulators for hire? Money derived from Industry US Food and Drug Administration, $3,416,000,000 (2022) The revolving door FDA, nine out of 10 of its past commissioners, 2006 to 2019 went on to secure roles linked with pharmaceutical companies 2005 UK, House of Commons’ health committee Industry funding could lead MHRA, to “lose sight of the need to protect and promote public health above all else as it seeks to win fee income from the companies.” BMJ investigation (2022) We found that industry money permeates the globe’s leading regulators, raising questions about their independence Sociologist Donald Light, Rowan University, New Jersey “Like the FDA, the TGA was founded to be an independent institute. However, being largely funded by fees from the companies whose products it is charged to evaluate is a fundamental conflict of interest, and a prime example of institutional corruption.” It is no longer possible for doctors and patients to receive unbiased, rigorous evaluations from drug regulators. FDA “It’s the opposite of having a trustworthy organisation independently and rigorously assessing medicines. They’re not rigorous, they’re not independent, they are selective, and they withhold data. Doctors and patients must appreciate how deeply and extensively drug regulators can’t be trusted so long as they are captured by industry funding.” Revisiting financial conflicts of interest in FDA advisory committees Large study, FDA advisory committee members over 15 years, those with financial interests solely in the sponsoring firm were more likely to vote in favour of the sponsor’s product.
